Zacks Research Brokers Lift Earnings Estimates for FMS

Fresenius Medical Care AG (NYSE:FMS) – Analysts at Zacks Research boosted their Q1 2025 earnings estimates for Fresenius Medical Care in a report issued on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now expects that the company will earn $0.44 per share for the quarter, up from their prior forecast of $0.39. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $2.01 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.60 EPS, FY2026 earnings at $2.19 EPS and FY2027 earnings at $2.07 EPS.

Other research analysts also recently issued research reports about the company. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, Truist Financial boosted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th.

Fresenius Medical Care Price Performance

Shares of FMS opened at $24.63 on Thursday. The firm has a market cap of $14.45 billion, a PE ratio of 20.35, a P/E/G ratio of 0.76 and a beta of 0.99. Fresenius Medical Care has a 1-year low of $17.93 and a 1-year high of $25.25. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The firm has a fifty day simple moving average of $23.82 and a two-hundred day simple moving average of $22.31.

Institutional Trading of Fresenius Medical Care

A number of hedge funds and other institutional investors have recently bought and sold shares of FMS. Millennium Management LLC grew its stake in shares of Fresenius Medical Care by 5,297.5% during the 4th quarter. Millennium Management LLC now owns 722,238 shares of the company’s stock valued at $16,351,000 after acquiring an additional 708,857 shares during the period. Integral Health Asset Management LLC boosted its position in shares of Fresenius Medical Care by 33.3% in the fourth quarter. Integral Health Asset Management LLC now owns 600,000 shares of the company’s stock worth $13,584,000 after purchasing an additional 150,000 shares during the period. Northern Trust Corp increased its stake in shares of Fresenius Medical Care by 45.9% in the fourth quarter. Northern Trust Corp now owns 362,190 shares of the company’s stock worth $8,200,000 after purchasing an additional 113,953 shares in the last quarter. Moran Wealth Management LLC increased its stake in shares of Fresenius Medical Care by 9.1% in the fourth quarter. Moran Wealth Management LLC now owns 254,710 shares of the company’s stock worth $5,767,000 after purchasing an additional 21,334 shares in the last quarter. Finally, ABC Arbitrage SA bought a new stake in shares of Fresenius Medical Care during the 4th quarter valued at $4,215,000. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.